Who Is the Best Suitor for Onyx Pharmaceuticals, Inc. (ONXX)?

Page 1 of 2

Cancer-drug maker Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) recently rejected an $8.7 billion unsolicited acquisition offer from Amgen, Inc. (NASDAQ:AMGN). Onyx also said that it is looking for potential suitors. The move has triggered speculations of a bidding war, sending the stock up 51.27% on Monday to $131.33.

Amgen, Inc. (NASDAQ:AMGN) had offered to pay $120 per share in cash, a 38.2% premium to Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)’s closing price of $86.82 on Friday, June 28. However, Onyx CEO Dr. Tony Coles felt that Amgen’s bid significantly undervalued his firm.

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)

Onyx has an envious product portfolio

Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) makes cancer drugs that generate high margins. It has liver- and kidney-cancer drug Nexavar, colon-cancer drug Stivarga and the newly launched Kyprolis. Analysts believe annual sales of Kyprolis could reach $3 billion. The peak sales of Nexavar and Stivarga could reach $1.4 billion and $1 billion, respectively. While Nexavar is established in the market, the other two drugs are yet to reach their sales peak. Onyx also has several promising drugs in the pipeline.

Large pharmaceutical companies have been eyeing cancer drugs because they require small sales forces and are usually covered by medical insurers. The potential acquirer has to take a bullish view on the future sales of Nexavar and Kyprolis. Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)’s breast cancer molecule palbociclib has also showed promising results. The company has licensed palbociclib to Pfizer, for which it would get an 8% global royalty when the product hits the market.

Amgen is desperate for acquisitions

Amgen, Inc. (NASDAQ:AMGN) plans to expand its business overseas and add new products to its portfolio as sales of its blockbuster drugs Aranesp and Epogen continue to decline. These two anemia drugs generated about $4 billion in sales in 2012. Moreover, some of Amgen’s major drugs will witness patent expiry starting 2015.

Amgen, Inc. (NASDAQ:AMGN) is planning to launch as many as six biosimilars by 2017. Kyprolis could complement Amgen’s product portfolio of cancer drugs and benefit from Amgen’s sales and marketing infrastructure. However, equity research firm ISI Group says that the $120-per-share share offer could work for Amgen only if it can attain 75% cost savings in sales and administration and 25% in R&D. That kind of cost savings looks impossible, given Amgen’s lack of experience in the hematological cancer market. And Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) has already rejected the $120 offer, so raising the bid would put further pressure on Amgen. If you are an Onyx shareholder, you shouldn’t pin much hope on Amgen.

So, who is the right fit?

After the rejection of Amgen, Inc. (NASDAQ:AMGN)’s unsolicited offer, there have been reports that large pharmaceutical companies are gearing up to enter the bidding war. Large firms are trying to boost their product portfolio and add new drugs to their pipeline as their major drugs go off patent. But I believe Bayer to be the best suitor for Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX).

Of Onyx’s $362 million revenues in 2012, 80% came from two drugs, Nexavar and Stivarga, sold in partnership with Bayer AG. Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) gets 20% royalty on the sales of Stivarga, and 50-50 profit split on Nexavar.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Laziest Countries in the World

The 10 Most Polluted Countries in the World

The 10 Most Dangerous Cities in America 2014

The Top 10 Gold Producing Countries in the World

The 10 Tallest Buildings in the World

The 10 Richest Stand Up Comedians in the World

The 10 Fattest Countries in the World

The 5 Best Summer Jobs for Teens

The 10 Most Religious Countries in the World Keeping the Faith

The 10 Most Educated Countries in the World

The 10 Most Popular Cell Phones in the World

The 10 Drunkest Countries in the World

The 10 Most Expensive Private Schools in the World

The 10 Smallest Countries in the World

Walking Dead Season 5 Spoilers You’ll Wish You Didn’t Know

The 10 Poorest Countries in the World

The 10 Greenest Countries in the World

The Top 10 Countries with the Highest Population in the World

The 10 Most Visited Countries in the World

The Top 10 Star Wars Characters in the Iconic Series

The 10 Most Expensive Android Phones in the World

5 Reasons Why The Illuminati Is Real and a Threat to Society

The 6 Scariest Halloween Costumes Ever Screamed At

The 4 Biggest Hedge Fund Managers in the World Today

The 15 Most Densely Populated Countries in the World

The 10 Biggest Tea Drinking Countries in the World

Top 6 Ways to Improve Your Checkout Process and Close Sales

The 5 Most Profitable Online Businesses You Can Start Today

The 20 Most Profitable Hospitals in the US

The 5 Most Profitable Home Businesses to Start

The 7 Teams that Will Win the Stanley Cup in 2015

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!